Tumor Biology

, Volume 36, Issue 2, pp 901–907 | Cite as

Increased expression of chitinase 3-like 1 is a prognosis marker for non-small cell lung cancer correlated with tumor angiogenesis

  • Xiao-Wei Wang
  • Cheng-Liang Cai
  • Jing-Ming Xu
  • Hai Jin
  • Zhi-Yun Xu
Research Article


Increasing evidence demonstrated that chitinase 3-like 1 (CHI3L1) was highly expressed and tightly associated with human tumor development and progression. However, its precise role in non-small cell lung cancer (NSCLC) remains to be delineated. The aim of this study was to examine CHI3L1 expression in patients with NSCLC and explore the relationship of CHI3L1 protein with clinicopathologic factors, tumor angiogenesis, and prognosis. CHI3L1 protein and intratumoral microvessels were examined by immunohistochemical staining in 95 NSCLC patients. Intratumoral microvessel density (MVD) was measured by counting CD34-positive immunostained endothelial cells. Quantitative real-time PCR (qRT-PCR) analyses were used to investigate the CHI3L1 expression status in tissues. Our result showed that CHI3L1 was significantly up-regulated in NSCLC tissues. In addition, univariate and multivariate analysis demonstrated that CHI3L1 protein overexpression and high MVD were significantly associated with tumor relapse. Although CHI3L1 overexpression and high MVD indicated poor overall survival (P < 0.05), multivariate analysis suggested that only CHI3L1 overexpression was an independent prognostic marker for unfavorable overall survival in patients with NSCLC (P < 0.05). The current results demonstrated that CHI3L1 may be a promising biomarker to identify individuals with poor prognostic potential and a possible target for anti-angiogenic therapy in patients with early stage NSCLC.


CHI3L1 Microvessel density Angiogenesis Prognosis Non-small cell lung cancer 


Conflicts of interest



  1. 1.
    Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011;61:212–36.CrossRefPubMedGoogle Scholar
  2. 2.
    Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al. Comparison of four chemotherapy regimens for advanced non small-cell lung cancer. N Engl J Med. 2002;346:92–8.CrossRefPubMedGoogle Scholar
  3. 3.
    Govindan R, Page N, Morgensztern D, Read W, Tierney R, Vlahiotis A. Changing epidemiology of small-cell lung cancer in the united states over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol. 2006;24(28):4539–44.CrossRefPubMedGoogle Scholar
  4. 4.
    Fry WA, Philips JL, Menck HR. Ten-year survey of lung cancer treatment and survival in hospitals in the United States: a national cancer data base report. Cancer. 1999;86:1867–76.CrossRefPubMedGoogle Scholar
  5. 5.
    Crino’ L, Weder W, van Meerbeeck J, Felip E, ESMO Guidelines Working Group. Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2011;21:v103–15.CrossRefGoogle Scholar
  6. 6.
    Zivanović S, Rackov LP, Vojvodić D, Vucetić D. Human cartilage glycoprotein 39—biomarker of joint damage in knee osteoarthritis. Int Orthop. 2009;33(4):1165–70.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Lee IA, Kamba A, Low D, Mizoguchi E. Novel methylxanthine derivative-mediated anti-inflammatory effects in inflammatory bowel disease. World J Gastroenterol. 2014;20(5):1127–38.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Johansen JS, Milman N, Hansen M, Garbarsch C, Price PA, Graudal N. Increased serum YKL-40 in patients with pulmonary sarcoidosis—a potential marker of disease activity? Respir Med. 2005;99(4):396–402.CrossRefPubMedGoogle Scholar
  9. 9.
    Nordenbaek C, Johansen JS, Halberg P, Wiik A, Garbarsch C, Ullman S, et al. High serum levels of YKL-40 in patients with systemic sclerosis are associated with pulmonary involvement. Scand J Rheumatol. 2005;34(4):293–7.CrossRefPubMedGoogle Scholar
  10. 10.
    Schiavon LL, Carvalho-Filho RJ, Narciso-Schiavon JL, Medina-Pestana JO, Lanzoni VP, Ferraz ML, et al. YKL-40 and hyaluronic acid (HA) as noninvasive markers of liver fibrosis in kidney transplant patients with HCV chronic infection. Scand J Gastroenterol. 2010;45(5):615–22.CrossRefPubMedGoogle Scholar
  11. 11.
    Mitsuhashi A, Matsui H, Usui H, Nagai Y, Tate S, Unno Y, et al. Serum YKL-40 as a marker for cervical adenocarcinoma. Ann Oncol. 2009;20(1):71–7.CrossRefPubMedGoogle Scholar
  12. 12.
    Shao R, Cao QJ, Arenas RB, Bigelow C, Bentley B, Yan W. Breast cancer expression of YKL-40 correlates with tumour grade, poor differentiation, and other cancer markers. Br J Cancer. 2011;105(8):1203–9.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Ushijima C, Tsukamoto S, Yamazaki K, Yoshino I, Sugio K, Sugimachi K. High vascularity in the peripheral region of non-small cell lung cancer tissue is associated with tumor progression. Lung Cancer. 2001;34(2):233–41.CrossRefPubMedGoogle Scholar
  14. 14.
    Brock CS, Lee SM. Anti-angiogenic strategies and vascular targeting in the treatment of lung cancer. Eur Respir J. 2002;19(3):557–70.CrossRefPubMedGoogle Scholar
  15. 15.
    Chaturvedi P, Gilkes DM, Takano N, Semenza GL. Hypoxia-inducible factor-dependent signaling between triple-negative breast cancer cells and mesenchymal stem cells promotes macrophage recruitment. Proc Natl Acad Sci U S A. 2014;111(20):E2120–9.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Tang H, Tian H, Yue W, Li L, Li S, Gao C, et al. Overexpression of LAPTM4B is correlated with tumor angiogenesis and poor prognosis in non-small cell lung cancer. Med Oncol. 2014;31(6):974.CrossRefPubMedGoogle Scholar
  17. 17.
    S-h L, Tian H, Yue W-M, Li L, Li W-J, et al. Overexpression of metastasis-associated protein 1 is significantly correlated with tumor angiogenesis and poor survival in patients with early-stage non-small cell lung cancer. Ann Surg Oncol. 2011;18:2048–56.CrossRefGoogle Scholar
  18. 18.
    Vartanian RK, Weidner N. Endothelial cell proliferation in prostatic carcinoma and prostatic hyperplasia: correlation with Gleason’s score, microvessel density, and epithelial cell proliferation. Lab Investig. 1995;73(6):844–50.PubMedGoogle Scholar
  19. 19.
    Wolf D, Wolf AM, Rumpold H, Fiegl H, Zeimet AG, et al. The expression of the regulatory T cell-specific forkhead box transcription factor foxP3 is associated with poor prognosis in ovarian cancer. Clin Cancer Res. 2005;11:8326–31.CrossRefPubMedGoogle Scholar
  20. 20.
    Harving ML, Christensen LH, Ringsholt M, Lausten GS, Petersen MM. YKL-40 expression in soft-tissue sarcomas and atypical lipomatous tumors. An immunohistochemical study of 49 tumors. Acta Orthop. 2014;85(2):195–200.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Libreros S, Garcia-Areas R, Keating P, Carrio R, Iragavarapu-Charyulu VL. Exploring the role of CHI3L1 in “pre-metastatic” lungs of mammary tumor-bearing mice. Front Physiol. 2013;4:392.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Özdemir E, Çiçek T, Kaya MO. Association of serum YKL-40 level with tumor burden and metastatic stage of prostate cancer. Urol J. 2012;9(3):568–73.PubMedGoogle Scholar
  23. 23.
    Castellano I, Mistrangelo M, Crudo V, Chiusa L, Lupo R, Ricardi U, et al. YKL-40 expression in anal carcinoma predicts shorter overall and disease-free survival. Histopathology. 2009;55(2):238–40.CrossRefPubMedGoogle Scholar
  24. 24.
    Urbich C, Kuehbacher A, Dimmeler S. Role of microRNAs in vascular diseases, inflammation, and angiogenesis. Cardiovasc Res. 2008;79:581–8.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  • Xiao-Wei Wang
    • 1
  • Cheng-Liang Cai
    • 1
  • Jing-Ming Xu
    • 1
  • Hai Jin
    • 1
  • Zhi-Yun Xu
    • 1
  1. 1.Department of Cardiothoracic Surgery, Changhai HospitalThe Second Military Medical UniversityShanghaiChina

Personalised recommendations